RT Journal Article
SR Electronic
T1 Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.13.20130211
DO 10.1101/2020.06.13.20130211
A1 Kibler, Marion
A1 Carmona, Adrien
A1 Marchandot, Benjamin
A1 Matsushita, Kensuke
A1 Trimaille, Antonin
A1 Kanso, Mohamad
A1 Dietrich, Laurent
A1 How-Choong, Cécile
A1 Odier, Albane
A1 Gennesseaux, Gabrielle
A1 Schramm, Ophélie
A1 Reydel, Antje
A1 Kindo, Michel
A1 Hoang, Minh
A1 Hess, Sébastien
A1 Sato, Chisato
A1 Caillard, Sophie
A1 Jesel, Laurence
A1 Morel, Olivier
A1 Ohlmann, Patrick
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130211.abstract
AB Background Although cardiovascular disease has been associated with an increased risk of coronavirus disease 2019 (COVID-19), no studies have reported its clinical course in patients with aortic stenosis who had undergone transcatheter aortic valve replacement (TAVR).Several observational studies have found an association between the A blood group and an increased susceptibility to SARS-CoV-2 infection, whereas the O blood group appears to be protective.Objective To investigate the frequency and clinical course of COVID-19 in a large sample of patients who had undergone TAVR and to determine the associations of the ABO blood group with disease occurrence and outcomes.Methods Patients who had undergone TAVR between 2010 and 2019 were included in this study and followed-up through the recent COVID-19 outbreak. The main outcomes were the occurrence and severity (hospitalization and/or death) of COVID-19 and their association with the ABO blood group.Results Of the 1125 patients who had undergone TAVR, 403 (36%) died before January 1, 2020, and 20 (1.8%) were lost to follow-up. The study sample therefore consisted of 702 patients. Among them, we identified 22 cases (3.1%) with COVID-19. Fourteen patients (63.6%) were hospitalized or died of disease. Multivariate analysis identified the A blood group (versus others) as the only independent predictor of COVID-19 in patients who had undergone TAVR (odds ratio [OR] = 6.32; 95% confidence interval [CI] = 2.11-18.92; p=0.001). The A blood group (versus others; OR = 8.27; 95% CI = 1.83-37.43, p=0.006) and a history of cancer (OR = 4.99; 95% CI = 1.64-15.27, p = 0.005) were significantly and independently associated with disease severity (hospitalization and/or death).Conclusions Patients who had undergone TAVR are vulnerable to COVID-19. The subgroup with the A blood group was especially prone to develop the disease and showed unfavorable outcomes.Condensed abstract Among 702 patients who had undergone TAVR between 2010 and 2019 and who were alive on January 1, 2020, 22 patients developed COVID-19. Fourteen patients (63.6%) were hospitalized or died of disease. The A blood group (versus others) was the only independent predictor of COVID-19. The A blood group and a history of cancer were significantly and independently associated with disease severity (hospitalization and/or death). Altogether these findings suggest that patients who had undergone TAVR are vulnerable to COVID-19. The subgroup with the A blood group was especially prone to develop the disease and showed unfavorable outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Institutional Review Board at the Strasbourg University Hospital (CE-2020-69)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe database is available online with the link below https://www.dropbox.com/s/cdny37mtajzp0cs/BDD%20COVID%20TAVI%20V1.xlsx?dl=0 ACE-2Angiotensin converting enzyme 2COVID-19coronavirus disease 2019CTComputed tomographyCVCardiovascularRhRhesusRT-PCRReverse transcriptase Polymerase Chain reactionSARS-CoV-2Severe Acute Respiratory Coronavirus-2TAVRTranscatheter aortic valve replacementWHOWorld Health Organization